Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion 44: Zongertinib + Chemotherapy +/- Pembrolizumab in HER2-mutant NSCLC
NCT07486817Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2026
- Primary completion
- Aug 2027
- Countries
- 7
01
Overview
A Phase 2 trial of zongertinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Jun 2026; status: recruiting.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07486817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486817.